Format

Send to

Choose Destination
See comment in PubMed Commons below
Psychiatry Res. 2015 Jul 30;228(1):121-7. doi: 10.1016/j.psychres.2015.04.026. Epub 2015 May 1.

Efficacy and safety of extract of Ginkgo biloba as an adjunct therapy in chronic schizophrenia: A systematic review of randomized, double-blind, placebo-controlled studies with meta-analysis.

Author information

1
Department of Pharmacy, Affiliated Wuxi No. 9 People׳s Hospital, Soochow University & Wuxi Hand Surgery Hospital, Liangxi Road 999, Wuxi, Jiangsu 214062, China. Electronic address: cxcyilanxs@aliyun.com.
2
Department of Pharmacy, Affiliated Wuxi Children׳s Hospital, Nanjing Medical University, Wuxi, Jiangsu 214023, China. Electronic address: hongyuan2011@aliyun.com.
3
Department of Pharmacy, Ningbo No. 6 Hospital, Ningbo, Zhejiang 315450, China.

Abstract

Our study was to review and evaluate the efficacy and safety of extract of Gb (EGb) as an adjuvant therapy to antipsychotics in chronic schizophrenia treatment. We searched Pubmed/Medline, Embase, PsycINFO, the Cochrane library, and especially the Chinese periodical databases. Finally, eight randomized, double-blind, placebo-controlled trials (RCTs) of 1033 patients were enrolled, with 571 cases in EGb group and 462 in placebo. The result showed that EGb had a significant difference in ameliorating total and negative symptoms of chronic schizophrenia as an adjuvant therapy to antipsychotics. Thus, the EGb therapy plus antipsychotics might be more efficacious. Although the studies describing adverse reactions showed no distinguishable difference between EGb and placebo group in mean total scores of Treatment Emergent Symptom Scale (TESS) or a Rating Scale for Extrapyramidal Side Effects (RSESE), the results of subscores varied in different studies. In addition, the severity of side effects of EGb might be related to its daily dosage. Therefore, the safety of EGb therapy in chronic schizophrenia treatment might need more evidence. And all of these eight trials were carried out in China; thus, the results might be restricted to the race and we need more high-quality studies of multi-center and randomized double-blind clinical trials to compare, analyze, and confirm the findings further.

KEYWORDS:

Chronic schizophrenia; EGb-761; Ginkgo biloba; Meta-analysis; Review

PMID:
25980333
DOI:
10.1016/j.psychres.2015.04.026
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center